Qure.ai, a global leader in AI-driven healthcare innovation, has expanded its executive leadership team with the appointment of Dr. Javier J. Zulueta as Chief Medical Officer, Pulmonology. The move underscores the company’s strategic focus on advancing lung health solutions and accelerating clinical deployment of its AI-powered tools in the United States and Europe. Dr. Zulueta, a renowned pulmonologist and pioneer in lung cancer screening, joins Qure.ai after serving as Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Chief of the Pulmonary Division at Mount Sinai Morningside Hospital in New York. His appointment brings more than 30 years of clinical, academic, and research leadership to the company, particularly in early lung cancer detection, pulmonary nodule management, and interventional pulmonology. In his new role, Dr. Zulueta will leverage his extensive experience to guide the clinical strategy behind Qure.ai’s Lung Cancer Suite, a set of AI-powered tools designed to detect lung nodules and support early diagnosis—critical for improving survival rates. He will also help shape the integration of these solutions into health systems and hospitals at scale. “Lung cancer remains the deadliest cancer globally, not because treatment isn’t available, but because it’s often detected too late,” said Dr. Zulueta. “We are at a pivotal moment where AI can transform incidental findings into life-saving interventions. Joining Qure.ai places me at the heart of this transformation—there is real potential to change the survival curve for lung cancer in a single generation.” Prashant Warier, Founder and CEO of Qure.ai, welcomed Dr. Zulueta to the team, stating, “We are thrilled to have Dr. Zulueta bring his unmatched global expertise in lung cancer screening and management to Qure.ai. His vision and clinical insight will be essential in advancing our AI solutions and driving their adoption across health systems worldwide.” Dr. Zulueta’s career includes founding and leading the Department of Respiratory Medicine at Clinica Universidad de Navarra in Pamplona, Spain—the first of its kind in the country. As Principal Investigator of the International Early Lung Cancer Action Program (IELCAP), he played a key role in launching Spain’s first lung cancer screening initiative. His contributions have helped shape national and international guidelines for early detection. This appointment follows a period of rapid growth for Qure.ai in the U.S., including the hiring of Jim Mercadante as Chief Commercial Officer earlier in 2025 and the addition of over a dozen new business development, sales, and strategic account management professionals across the country. The company was recently recognized as a TIME100 Most Influential Company 2025 for its use of AI to improve access and diagnosis of high-burden diseases globally. With deployments in over 100 countries and 18 FDA-cleared AI findings, Qure.ai continues to expand its impact in diagnosing tuberculosis, lung cancer, and neurocritical conditions. The company operates regional offices in New York, London, Dubai, and Mumbai, reinforcing its commitment to delivering equitable, AI-powered healthcare solutions worldwide.